No title
There has been an increased interest in ways of measuring the value of new therapeutic options in oncology. An example of this in a European context is the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). The purpose of this study is to analyse how the value scales, exemplified with ESMO-MCBS, developed mainly to assist decisions by physicians, relate to other measures of clinical benefit and
